Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction.

Background: Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis. This analysis evaluated the efficacy of tezepelumab in patients with severe, uncontrolled asthma and PAO.

Catalytic evaluation of MOF-808 with metallic centers of Zr(IV), Hf(IV) and Ce(IV) in the acetalization of benzaldehyde with methanol.

In the context of climate change, it is of utmost importance to replace the use of fossil fuels as raw material in areas of industrial interest, for example, in the production of chemical inputs. In this context, a viable option is biomass, since by subjecting it to chemical processes such as pyrolysis, it is possible to obtain platform molecules that are the basis for the generation of value-added chemical products. Acetals are molecules obtained from biomass derivatives, which have various applications in cosmetic chemistry, in the pharmaceutical industry as intermediates or final compounds, food additives, among others.

Model Predictive Control (MPC) of a Countercurrent Flow Plate Heat Exchanger in a Virtual Environment.

This research proposes advanced model-based control strategies for a countercurrent flow plate heat exchanger in a virtual environment. A virtual environment with visual and auditory effects is designed, which requires a mathematical model describing the real dynamics of the process; this allows parallel fluid movement in different directions with hot and cold temperatures at the outlet, incorporating control monitoring interfaces as communication links between the virtual heat exchanger and control applications. A multivariable and non-linear process like the plate and countercurrent flow heat exchanger requires analysis in the controller design; therefore, this work proposes and compares two control strategies to identify the best-performing one.

Comparative Performance of Kevlar, Glass and Basalt Epoxy- and Elium-Based Composites under Static-, Low- and High-Velocity Loading Scenarios-Introduction to an Effective Recyclable and Eco-Friendly Composite.

In general, the majority of fiber-reinforced polymer composites (FRPs) used in structural applications comprise carbon, glass, and aramid fibers reinforced with epoxy resin, with the occasional utilization of polyester and vinyl ester resins. This study aims to assess the feasibility of utilizing recyclable and sustainable materials to create a resilient composite suitable for structural applications, particularly in scenarios involving low-velocity and high-velocity impact (LVI, HVI) loading. The paper presents a comparative analysis of the performance of E-glass, aramid, and eco-friendly basalt-reinforcing fabrics as reinforcement fibers in both thermosetting (epoxy) and recyclable thermoplastic (Elium) resins.

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.

Introduction: Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbations over 52 weeks compared with placebo in patients with severe, uncontrolled asthma. This analysis assessed the efficacy of tezepelumab in reducing asthma exacerbations in various clinically relevant subgroups of patients in NAVIGATOR.

Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.

Background: Long-term tezepelumab treatment in the DESTINATION study (NCT03706079) resulted in reduced asthma exacerbations, reduced biomarker levels, and improved lung function and symptom control in patients with severe, uncontrolled asthma.

Objective: To explore the time course of changes in biomarkers and clinical manifestations after treatment cessation after 2 years of tezepelumab treatment.

Methods: DESTINATION was a 2-year, phase 3, multicenter, randomized, placebo-controlled, double-blind study of tezepelumab treatment in patients (12-80 years old) with severe asthma.

Effect of hydrochar-doping on the performance of carbon felt as anodic electrode in microbial fuel cells.

In this study, the feasibility of using hydrochars as anodic doping materials in microbial fuel cells (MFCs) was investigated. The feedstock used for hydrochar synthesis was metal-polluted plant biomass from an abandoned mining site. The hydrochar obtained was activated by pyrolysis at 500 °C in N atmosphere.

Characterization of Low- and High-Velocity Responses of Basalt-Epoxy and Basalt-Elium Composites.

Currently, fiber-reinforced polymer composites (FRPs) used for demanding structural applications predominantly utilize carbon, glass, and aramid fibers embedded in epoxy resin, albeit occasionally polyester and vinyl ester resins are also used. This study investigates the feasibility of employing recyclable and sustainable materials to formulate a composite suitable for load-bearing structural applications, particularly in scenarios involving low-velocity and high-velocity impacts (LVIs and HVIs, respectively). The paper presents a comparative analysis of the performance of basalt-Elium, a fully recyclable, sustainable, and environmentally friendly composite, with an epoxy-based counterpart.

New blend of renewable bioplastic based on starch and acetylated xylan with high resistance to oil and water vapor.

Renewable materials of biological origin exhibit attractive properties in relation to traditional plastics, as they can be partially or completely replaced, thereby reducing environmental impacts. Hemicelluloses are a group of polysaccharides that have expanded applications when acetylated. Acetylation can improve the mechanical strength and water vapor barrier properties of xylan-based bioplastics.

Predicting the final grade using a machine learning regression model: insights from fifty percent of total course grades in CS1 courses.

This article introduces a model for accurately predicting students' final grades in the CS1 course by utilizing their grades from the first half of the course. The methodology includes three phases: training, testing, and validation, employing four regression algorithms: AdaBoost, Random Forest, Support Vector Regression (SVR), and XGBoost. Notably, the SVR algorithm outperformed the others, achieving an impressive R-squared () value ranging from 72% to 91%.

Geographic variation in disease burden among patients with severe persistent asthma in the United States.

Background: In the United States, a few studies have evaluated geographic variation of severe asthma at the subnational level.

Objective: To assess state-level geographic variation in the prevalence and characteristics of severe persistent asthma in the United States.

Methods: Patients aged above or equal to 12 years with severe persistent asthma were identified using nationally representative data from IQVIA open-source Medical/Pharmacy Claims and PharMetrics Plus databases (January 2019-December 2020).

Early prediction of student performance in CS1 programming courses.

There is a high failure rate and low academic performance observed in programming courses. To address these issues, it is crucial to predict student performance at an early stage. This allows teachers to provide timely support and interventions to help students achieve their learning objectives.

Enhancing c-Si Solar Cell Efficiency in the UV Region: Photophysical Insights into the Use of Eu Complexes for Down-Shifting Layer Applications.

[Eu(DPIQC)] (where DPIQC = 3-(diphenyl phosphoryl)-1-isoquinolinecarboxylate), a luminescent europium complex with antenna ligands, has been carefully embedded within a polyvinyl butyral (PVB) matrix and the resulting material was used to prepare films used as luminescent down-shifting layers (LDSLs) for crystalline Si-based solar cells. The films were characterized using photoluminescence spectroscopy, atomic force spectroscopy (AFM), UV-Vis spectroscopy, and fluorescence microscopy. The AFM analysis shows films with low surface roughness, while fluorescence microscopy revealed that the Eu complex embedded in PVB assumed a spheroidal configuration, a morphology especially beneficial for optical applications.

Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.

Patients with uncontrolled, allergic severe asthma may be prescribed biologic therapies to reduce exacerbations and improve disease control. Randomized controlled trials (RCTs) of these therapies have differed in design, with varying results overall and by baseline blood eosinophil count (BEC). This study describes published annualized asthma exacerbation rate (AAER) reductions from RCTs in patients with allergic severe asthma, overall and by baseline BEC category.

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.

Purpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symptom control versus placebo in adults and adolescents with severe, uncontrolled asthma. We assessed the efficacy of tezepelumab in patients with severe asthma with or without nasal polyps (NPs) in the 2 years before randomization in NAVIGATOR.

Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).

Background: Asthma exacerbation frequencies vary throughout the year owing to seasonal triggers. Tezepelumab is a human monoclonal antibody that targets thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab significantly reduced the annualized asthma exacerbation rate (AAER) vs placebo in patients with severe, uncontrolled asthma.

Incremental cost burden among patients with severe uncontrolled asthma in the United States.

The economic burden of severe asthma and severe uncontrolled asthma (SUA) is significant. Updated assessments of health care resource utilization (HCRU) and cost are needed given the increase in treatment options and updates to guidelines in recent years. To describe all-cause and asthma-related HCRU and costs among patients with SUA vs patients with nonsevere asthma in the United States using real-world data.

Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.

Background: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function, asthma control, and health-related quality of life compared with placebo in patients with severe, uncontrolled asthma. However, little is known about the impact of tezepelumab on healthcare utilization (HCU) in these patients.

Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.

Introduction: Randomized controlled trials (RCTs) of biologics in patients with severe, uncontrolled asthma have shown differential results by baseline blood eosinophil count (BEC). In the absence of head-to-head trials, we describe the effects of biologics on annualized asthma exacerbation rate (AAER) by baseline BEC in placebo-controlled RCTs. Exacerbations associated with hospitalization or an emergency room visit, pre-bronchodilator forced expiratory volume in 1 s, Asthma Control Questionnaire score, and Asthma Quality of Life Questionnaire score were also summarized.

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.

Tezepelumab reduced exacerbations in patients with severe, uncontrolled asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric oxide levels, and irrespective of allergy status, in the phase 2b PATHWAY (Study to Evaluate the Efficacy and Safety of MEDI9929 [AMG 157] in Adult Subjects With Inadequately Controlled, Severe Asthma; NCT02054130) and phase 3 NAVIGATOR (Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma; NCT03347279) trials. To examine the efficacy and safety of tezepelumab in additional clinically relevant subgroups using pooled data from PATHWAY and NAVIGATOR. PATHWAY and NAVIGATOR were randomized, double-blind, placebo-controlled trials with similar designs.

Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma.

Background: Patients with severe asthma (SA) experience a high disease burden, often precipitated by exposure to disease triggers.

Objective: To evaluate the prevalence and effects of patient-reported triggers on asthma disease burden in a cohort of subspecialist-treated patients with SA in the United States.

Methods: CHRONICLE is an observational study of adults with SA receiving biologics or maintenance systemic corticosteroids or whose disease is uncontrolled on high-dosage inhaled corticosteroids and additional controllers.